Estee Lauder Companies (T – Consensus indicates upside potential of 11.8%
Estée Lauder Enterprises (T found using the ticker (EL) now have 20 analysts covering the stock with the consensus suggesting a rating of “Buy.” The range between the high target price and the low target price is between 367 and 270 with an average TP of 335.75. Given that the previous close of shares was at 300.22, this indicates that there is a potential upside of 11.8%. The 50 day MA is 301.75 and the 200 moving average is now rising to 280.72. The company has a market capitalization of $ 109,921 million. Company website: http://www.elcompanies.com
The Estée Lauder Companies Inc. manufactures and markets skin care, makeup, fragrance and hair care products. The company offers a range of skin care products including moisturizers, serums, cleansers, toners, body care, exfoliators, acne care and oil correctors, face masks , cleaning devices and sun products; and makeup products, such as lipsticks, lip glosses, mascaras, foundations, eye shadows, nail polishes and powders, as well as compacts, brushes and others makeup tools. It also supplies perfumery products in various forms including eau de parfum sprays and colognes, as well as lotions, powders, creams, candles and soaps; and hair care products which include shampoos, conditioners, styling products, treatments, finishing sprays and hair coloring products, as well as ancillary products and services. The company offers its products under Estée Lauder, Aramis, Clinique, Lab Series, Origins, MÂ · A · C, Bobbi Brown, La Mer, Aveda, Jo Malone London, Bumble and bumble, Darphin, Smashbox, Le Labo, Editions de Parfums Frédéric Malle, GLAMGLOW, By Kilian, BECCA, Too Faced, RODIN olio lusso, FLIRT !, Kiton and Tom Ford. It also holds licensing agreements for the brands Tommy Hilfiger, Donna Karan New York, DKNY, Michael Kors, Ermenegildo Zegna, Dr Andrew Weil, TOM FORD BEAUTY, AERIN and Tory Burch. The company sells its products through department stores, specialty multi-retailers, upscale perfume and drug stores, salons and spas; independent stores; its own authorized retailer websites; third-party online shopping malls; shops at airports and on cruise ships; inflight and duty free shops; and self-selected points of sale. It is present in the Americas, Europe, the Middle East, Africa and Asia-Pacific. The Estée Lauder Companies Inc. has a joint development agreement with Atropos Therapeutics Inc. to discover senomodulators. The company was founded in 1946 and is headquartered in New York, New York.